Neutrogena Norwegian Formula 40% dermatological cream

国家: 英国

语言: 英文

来源: MHRA (Medicines & Healthcare Products Regulatory Agency)

有效成分:

Glycerol

可用日期:

Johnson & Johnson Ltd

ATC代码:

n/a

INN（国际名称）:

Glycerol

剂量:

400mg/1gram

药物剂型:

Cutaneous cream

给药途径:

Cutaneous

类:

No Controlled Drug Status

处方类型:

Valid as a prescribable product

產品總結:

BNF: 13020100; GTIN: 5012716124012

资料单张

BRAILLE
neutrogena norwegian
formula dermatological
cream

产品特点

OBJECT 1
NEUTROGENA NORWEGIAN FORMULA DERMATOLOGICAL
CREAM
Summary of Product Characteristics Updated 21-Jun-2016 | Johnson &
Johnson Ltd
1. Name of the medicinal product
Neutrogena Norwegian Formula Dermatological Cream
2. Qualitative and quantitative composition
The cream contains Glycerol Ph. Eur. 40% w/w as the active ingredient.
For a full list of excipients see section 6.1.
3. Pharmaceutical form
Cream for topical use.
White thick cream
4. Clinical particulars
4.1 Therapeutic indications
For the management of dry skin problems associated with eczema,
psoriasis, dermatitis, ichthyosis and
winter dry skin.
4.2 Posology and method of administration
Apply regularly to the affected area.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Severely broken skin.
4.4 Special warnings and precautions for use
Contains parahydroxybenzoates which may cause allergic reactions
(possibly delayed).
Contains cetostearyl alcohol which may cause local skin reactions
(e.g. contact dermatitis).
4.5 Interaction with other medicinal products and other forms of
interaction
No interaction studies have been performed.
4.6 Fertility, pregnancy and lactation
No limitation on the use of Neutrogena Norwegian Formula
Dermatological Cream is imposed by
pregnancy or lactation.
4.7 Effects on ability to drive and use machines
Not relevant
4.8 Undesirable effects
Post-marketing data:
Adverse drug reactions (ADRs) identified during post-marketing
experience with Glycerol are included in
the table below, the frequencies are provided according to the
following convention:
Very common ≥1/10
Common ≥1/100 and <1/10
Uncommon ≥1/1,000 and <1/100
Rare ≥1/10,000, and <1/1,000
Very rare <1/10,000
Not known (cannot be estimated from the available data)
Table 1: Adverse Drug Reactions Identified during Post-Marketing
Experience with Glycerol by
Frequency Category estimated from Spontaneous Reporting Rates
Body system
Incidence
Reported adverse event
Immune System Disorders
Not known
H